Cargando…
Methodology to Assess Clinical Liver Safety Data
Analysis of liver safety data has to be multivariate by nature and needs to take into account time dependency of observations. Current standard tools for liver safety assessment such as summary tables, individual data listings, and narratives address these requirements to a limited extent only. Usin...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4212156/ https://www.ncbi.nlm.nih.gov/pubmed/25352326 http://dx.doi.org/10.1007/s40264-014-0184-5 |
_version_ | 1782341663395414016 |
---|---|
author | Merz, Michael Lee, Kwan R. Kullak-Ublick, Gerd A. Brueckner, Andreas Watkins, Paul B. |
author_facet | Merz, Michael Lee, Kwan R. Kullak-Ublick, Gerd A. Brueckner, Andreas Watkins, Paul B. |
author_sort | Merz, Michael |
collection | PubMed |
description | Analysis of liver safety data has to be multivariate by nature and needs to take into account time dependency of observations. Current standard tools for liver safety assessment such as summary tables, individual data listings, and narratives address these requirements to a limited extent only. Using graphics in the context of a systematic workflow including predefined graph templates is a valuable addition to standard instruments, helping to ensure completeness of evaluation, and supporting both hypothesis generation and testing. Employing graphical workflows interactively allows analysis in a team-based setting and facilitates identification of the most suitable graphics for publishing and regulatory reporting. Another important tool is statistical outlier detection, accounting for the fact that for assessment of Drug-Induced Liver Injury, identification and thorough evaluation of extreme values has much more relevance than measures of central tendency in the data. Taken together, systematical graphical data exploration and statistical outlier detection may have the potential to significantly improve assessment and interpretation of clinical liver safety data. A workshop was convened to discuss best practices for the assessment of drug-induced liver injury (DILI) in clinical trials. |
format | Online Article Text |
id | pubmed-4212156 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-42121562014-11-05 Methodology to Assess Clinical Liver Safety Data Merz, Michael Lee, Kwan R. Kullak-Ublick, Gerd A. Brueckner, Andreas Watkins, Paul B. Drug Saf Review Article Analysis of liver safety data has to be multivariate by nature and needs to take into account time dependency of observations. Current standard tools for liver safety assessment such as summary tables, individual data listings, and narratives address these requirements to a limited extent only. Using graphics in the context of a systematic workflow including predefined graph templates is a valuable addition to standard instruments, helping to ensure completeness of evaluation, and supporting both hypothesis generation and testing. Employing graphical workflows interactively allows analysis in a team-based setting and facilitates identification of the most suitable graphics for publishing and regulatory reporting. Another important tool is statistical outlier detection, accounting for the fact that for assessment of Drug-Induced Liver Injury, identification and thorough evaluation of extreme values has much more relevance than measures of central tendency in the data. Taken together, systematical graphical data exploration and statistical outlier detection may have the potential to significantly improve assessment and interpretation of clinical liver safety data. A workshop was convened to discuss best practices for the assessment of drug-induced liver injury (DILI) in clinical trials. Springer International Publishing 2014-10-29 2014 /pmc/articles/PMC4212156/ /pubmed/25352326 http://dx.doi.org/10.1007/s40264-014-0184-5 Text en © The Author(s) 2014 https://creativecommons.org/licenses/by-nc/4.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. |
spellingShingle | Review Article Merz, Michael Lee, Kwan R. Kullak-Ublick, Gerd A. Brueckner, Andreas Watkins, Paul B. Methodology to Assess Clinical Liver Safety Data |
title | Methodology to Assess Clinical Liver Safety Data |
title_full | Methodology to Assess Clinical Liver Safety Data |
title_fullStr | Methodology to Assess Clinical Liver Safety Data |
title_full_unstemmed | Methodology to Assess Clinical Liver Safety Data |
title_short | Methodology to Assess Clinical Liver Safety Data |
title_sort | methodology to assess clinical liver safety data |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4212156/ https://www.ncbi.nlm.nih.gov/pubmed/25352326 http://dx.doi.org/10.1007/s40264-014-0184-5 |
work_keys_str_mv | AT merzmichael methodologytoassessclinicalliversafetydata AT leekwanr methodologytoassessclinicalliversafetydata AT kullakublickgerda methodologytoassessclinicalliversafetydata AT bruecknerandreas methodologytoassessclinicalliversafetydata AT watkinspaulb methodologytoassessclinicalliversafetydata |